Fastnet Equity Share Discussion Threads

[barnes4] 31/3/2016 19:25

I would rather buy at 3p than 3.1p

[soul limbo] 31/3/2016 19:25

and buyers of the equity are getting a pharma company that already has already amassed eur54m worth of research (funded by a massive charitable foundation)

[barnes4] 31/3/2016 19:24

How do you buy this placing?

[soul limbo] 31/3/2016 19:18

i believe only c30% will be in free float once all done and dusted

[galacticus] 31/3/2016 19:14

Is it not obvious holders sold to get placing stock plus warrants. I hear raise closes tomorrow so liquidity on ask will dry up then and should trend to 4p area. Post RTO look at other companies at same stage. Only 3 or four of them all at 10 times cap plus where FAST will be at 50 mill. Just look at the register look at Friel and Cove look at Harry and a bedroom business into a billion plus cap company.

Not hard to join the dots really.

[jacksonpollack] 31/3/2016 18:43

Was expecting more today. Bit of a damp squib really, like most shares on aim

[buffythebuffoon] 31/3/2016 17:12

Ditto Pap (to the pure and applied), but only 42 years ago!

I then drifted off to the biosciences, and although I have little direct experience of biopharmaceuticals, I am very aware how long it takes to get products through to market. We have, or rather, will have, a nicely balanced range of products in AMYT IMHO.

Buffy

[sea7] 31/3/2016 17:02

Pap, I sold all my fastnet at 2.74p, so yep a tad annoyed as that plan of buying back in much lower didn't pan out, as the suspension came first, however, at the initial look at todays news, I thought 3p is about right to be on the same level as the placing at 24p post consolidation.

Whilst £10m may be ok to be going on with, it does state additional funding for existing products will be needed, so I am taking a longer view and seeing the likelyhood of a lower entry after the re-organisation and placing, once they start burning through that cash.

Birken has had around eur54m of funding to get this far. I am slightly bearish on the fact that, whilst it has approval,there isn't any real sales data, for take up and none of the acquisitions have much revenue to speak of. birkens imlan generated around eur850k last year iirc.

I guess thats the gamble eh!!!

[birotop] 31/3/2016 16:55

That just about sums it up....

[papillon] 31/3/2016 16:52

I got 2 A levels in maths (pure and applied) 53 years ago, buffy and for the fun of it did an OU degree course (mostly in pure maths) many years ago.

[sea7] 31/3/2016 16:51

Good point pap, I put eur instead of gbp tks for pointing that out!!!!

[papillon] 31/3/2016 16:46

"It won't be long before the additional funding is sought, if not already being looked at."

You seem to be a bit bearish, sea7. Don't think me an old cynic, but is that because you said you had sold all of your FAST shares pre the February suspension at circa 2.6p?

We shall see what happens. You don't get something for nothing.

PS. "This will leave the EUR10 million from the placing to fund the eb trials."

Check the RNS again buddy. The placing is intended to raise £10m, NOT EUR10m.

£10m is an adequate sum to be getting on with for the time being, IMO. Especially as Episalvan is already on sale ... "The drug received formal marketing approval from the European Commission on 14 January 2016 for the treatment in adults for accelerated healing of PTWs." You never know it might generate some much needed revenue in the short term; stranger things have happened! LOL.

[buffythebuffoon] 31/3/2016 16:37

Pap, looks like it should be 3.05.

By the way, I've always been very aware of arithmetic just being one component of mathematics since I was young. My dad could multiply two three digit numbers in his head, but wouldn't have been able to tell you the difference between algebra and trigonometry!

Buffy

[karlm] 31/3/2016 16:31

I for one am happy to hold my 300k and see how this story unfolds. I have every confidence in their actions and indeed the amazing board they have lined up.

[karlm] 31/3/2016 16:29

Wow, sea7, since saying you'll be a buyer sub 3p this morning ; you have been very negative across numerous b boards. I guess you'll do and say what you can to try and push the price down.

Each to their own.

[papillon] 31/3/2016 16:26

Strange. Someone just paid 3.50p for 50k (4:05pm). An error?

[sea7] 31/3/2016 16:23

The birken sellers are getting...

initial eur 1 million settled on signature of birken spa
another eur 150k on completion

milestone payments upto eur50 million, of which eur10 million is payable on admission

royalties of 6-9% of episalvan sales for 10 years from first commercial sale.

and shares in amryt totalling 30% of the fully diluted issued share capital

...........

After paying out eur11.1million - the old cash balance from fastnet equity is about gone.

Then..

pay $100k in cash for somtherapeutics less liabilities if over $150k
pay $4.15m in shares for sompharmaceuticals.

This will leave the EUR10 million from the placing to fund the eb trials.

It won't be long before the additional funding is sought, if not already being looked at.

[punter6] 31/3/2016 16:20

Broker just passed on to me details of a 45 minute presentation by Joe Wiley & Rory Nealon to take place at the Double Tree by Hilton (the old Burlington Hotel) in Dublin on Wednesday 6th April next at 5 p.m.,followed by a Q & A session.
(Ray Stafford will also attend)

Afraid I can't make it myself but if anyone here can please let us know how it goes.

[papillon] 31/3/2016 15:55

free stock charts from uk.advfn.com


A potentially bullish Cup and Handle chart pattern has formed, today, on the FAST closing prices chart. 4p looks achievable in the short term before the 8 for 1 consolidation and name change takes place. I suppose it all depends on how much demand there is for the placing shares and if investor demand exceeds the supply.

[bigwavedave] 31/3/2016 15:50

AMRYT interview:


[...]

[sea7] 31/3/2016 14:42

yep, they are likely to be after more cash soon...

from the rns today..

The Enlarged Group will utilise the net proceeds of the placing to focus on the opportunity presented within the EB market as described below. Subject to securing additional capital, which may come from alternative sources such as licencing deals or venture debt, the Enlarged Group would have the ability to exploit its other assets, Episalvan in respect of PTWs which has been approved for use in Europe and its preclinical assets focused on Acromegaly and Cushing's disease,

[papillon] 31/3/2016 14:36

No offence intended buffy. Just a light hearted comment on my part. I'm sure maths is one of your stronger points, just like it's one of mine. And you are correct; I should have written arithmetic instead of maths, but the latter is shorter to type.

[buffythebuffoon] 31/3/2016 14:28

Pap,

How do you know it's my maths that need attention, and not my typing? 😃

In fact, maths is one of my stronger points, and not just arithmetic, which is what you would more accurately be disparaging!

I didn't actually mean to say that. In fact I lost my thread slightly after trying to dig too deeply into the impact of the deferred shares. (I was wondering whether there was a subtle con, but even if the company bought them back for 1p I don't think they could dilute us any more by converting them in some way).


What's more important is the value of the new share in the company that we each own. That's very much unknown to us really.

As for a 'respectable share price', not only is it still a penny share, but, as shown so clearly with PCI, it gives greater scope for more dilution; which is basically what Friel said in the RNS!

Buffy

[papillon] 31/3/2016 13:57

"The Mcap will therefore be 5 times bigger and we'll have 1/8 the number of shares."

I can see maths isn't your strong point buffy. Before the acquisition 345.37m. After the acquisition and share consolidation we will have 208.34m shares. That doesn't equate to 1/8th the number of shares!

The Mkt Cap @ 24p per share (after the acquisition and share consolidation) will be circa £50m and with circa 3/5ths the number of shares in issue.

Hopefully a £50m Mkt Cap and a more respectable share price will attract some institutional investors.